We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $14.83 · 3 analysts
Stored first · Google News · Yahoo Finance (English)
Chimera Investment (NYSE:CIM) Shares Cross Above 200-Day Moving Average - Should You Sell? - MarketBeat
Chimera Investment (NYSE:CIM) Shares Cross Above 200-Day Moving Average - Should You Sell? MarketBeat
CIM stock holds steady as Chimera Investment navigates the mortgage REIT cycle - ad-hoc-news.de
CIM stock holds steady as Chimera Investment navigates the mortgage REIT cycle ad-hoc-news.de
Chimera Investment Corporation 7.75% Series C Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock - TradingView
Chimera Investment Corporation 7.75% Series C Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock TradingView
CIM - Chimera Investment Corp Latest SEC Filings - Finviz
CIM - Chimera Investment Corp Latest SEC Filings Finviz
CIM - Chimera Investment Corp Options - Finviz
CIM - Chimera Investment Corp Options Finviz
Chimera Investment Corp (CIM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Chimera Investment Corp (CIM) Financial Health: Profitability & Balance Sheet Analysis TradingKey
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 05. | After market close (AMC) | $0.5 | — | — | $80.9M | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2025. 11. 19. | UBS | — | Maintain | Buy → Buy | — | UBS: Buy |
| 2025. 07. 11. | UBS | — | Maintain | Buy → Buy | — | UBS: Buy |
| 2025. 07. 10. | Keefe, Bruyette & Woods | — | Maintain | Market Perform → Market Perform | — | Keefe, Bruyette & Woods: Market Perform |
| 2025. 05. 14. | UBS | — | Upgrade | Neutral → Buy | — | UBS: Neutral → Buy |
| 2025. 01. 23. | JMP Securities | — | Maintain | Market Perform → Market Perform | — | JMP Securities: Market Perform |
| 2024. 08. 08. | Keefe, Bruyette & Woods | — | Maintain | Market Perform → Market Perform | — | Keefe, Bruyette & Woods: Market Perform |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.